1stOncology™: Cancer Intelligence Service – Page 1401 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference

On December 18, 2025 Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, reported that CEO Uzi Sofer and CFO Raphi Levy will present a corporate overview and update at the J.P. Morgan 2026 Healthcare Conference on Thursday, January 15, 2026 at 11:15am PT / 2:15pm ET, in San Francisco, CA, and will host institutional investor meetings at the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Event: J.P. Morgan 2026 Healthcare Conference
Format: Presentation and 1-on-1 Meetings
Date: January 15, 2026
Time: 11:15AM PT – 11:55AM PT
Location: Westin St. Francis, San Francisco, CA

Webcast: Link will be posted on the "Events & Presentations" page in the Investor Relations section on the Company’s website at View Source

Please reach out to your J.P. Morgan representative to schedule 1-on-1 meetings with Mr. Sofer and Mr. Levy.

(Press release, Alpha Tau Medical, DEC 18, 2025, View Source [SID1234661526])

FoRx Therapeutics Announces USD 50M Series A Financing, Enabling Clinical Data Readout for Potential Best-in-Class PARG Inhibitor

On December 18, 2025 FoRx Therapeutics, a clinical-stage biotechnology company developing precision anti-cancer therapeutics, reported the close of an insider-led USD 50 million (CHF 40 million) Series A financing. The funding will be used to advance Phase 1 clinical development of its lead drug candidate, FORX-428, a potential best-in-class PARG (poly (ADP-ribose) glycohydrolase) inhibitor designed to target and disrupt the DNA Damage Response (DDR) in advanced solid tumors.

Existing investors including EQT Life Sciences, Pfizer Ventures, Novartis Venture Fund and M Ventures participated in the financing including a first closing in June 2024, which provided funding through the Investigational New Drug (IND) application for FORX-428 and the initiation of the Phase 1 trial.

Tarig Bashir, CEO of FoRx Therapeutics, said: "The FoRx team is proud to have earned the continued trust and conviction of this sophisticated syndicate of leading strategic and specialist investors. The funds from this investment will allow us to achieve initial clinical readout in our ongoing Phase 1 trial of FORX-428, which has shown very strong anti-tumor efficacy in multiple preclinical in vitro and in vivo tumor models. We are looking forward to reinforcing its best-in-class PARG inhibitor characteristics and potential to make a significant difference to patients, with initial clinical data expected in mid-2026."

The discovery that distinct genetic subsets of cancer are exceptionally vulnerable to drugs that interfere with the DNA Damage Response (DDR) led to the approval of PARP inhibitors more than 10 years ago, transforming cancer treatment. FoRx is pursuing a next-generation DDR target, PARG, which shows significant potential as a new treatment for patients whose cancers are resistant to, or have become resistant to, PARP inhibitors.

Vincent Brichard (EQT Life Sciences), Board member at FoRx Therapeutics, said: "Advances in PARG inhibition hold significant potential as a therapeutic strategy in Oncology. Our syndicate’s continued support of FoRx reflects our confidence in both, the lead candidate FORX-428, and the strong progress achieved by its experienced management team."

FoRx’s ongoing first-in-human Phase 1study of FORX-428, a novel PARG inhibitor targeting the DDR in advanced solid tumors is progressing as planned, with initial data readout expected by mid-2026. The open-label study, which began recruitment in August 2025 in the United States, is evaluating safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced solid tumors who have exhausted standard-of-care options.

FORX-428 is a proprietary, orally available small molecule inhibitor of poly (ADP-ribose) glycohydrolase (PARG). PARG is a DNA repair enzyme considered important for the survival of certain genetically defined cancers with specific DDR deficiencies or high replication stress. In preclinical studies, FORX-428 demonstrated robust anti-tumor activity across multiple solid tumor types underscoring the novel compound’s outstanding potential in both monotherapy and combination settings. FORX-428 was well tolerated, demonstrating drug-like pharmacology and a favorable safety profile.

(Press release, FoRx Therapeutics, DEC 18, 2025, View Source [SID1234661525])

Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference

Talus Bio Announces New Collaboration with PRISM BioLab to Discover Novel Modulators of Transcription Factor and Protein-Protein Interaction Targets

On December 17, 2025 Talus Bioscience, Inc. ("Talus Bio"), an AI-enabled regulome therapeutics company, reported a strategic collaboration with PRISM BioLab Co., Ltd. ("PRISM") to accelerate the discovery and development of novel small-molecule modulators of transcription factor (TF) and protein-protein interaction (PPI) targets. The collaboration combines Talus Bio’s pioneering regulome profiling and AI-guided drug discovery platform with PRISM’s innovative chemistry.

"This collaboration gives us an unprecedented opportunity to pursue targets that have resisted conventional drug discovery," said Alex Federation, PhD, CEO and Co-Founder of Talus Bio. "Integrating PRISM’s chemistry with Talus’ regulome profiling and AI models allows us to see, in real time, how compounds reshape transcriptional networks in human cells. It’s a step-change in our ability to drug the undruggable."

Under the agreement, the companies will deploy PRISM’s proprietary small-molecule libraries in Talus Bio’s AI-guided regulome profiling screens to identify and optimize novel compounds against high-value TF and PPI targets. The collaboration aims to generate first-in-class chemical matter with direct functional effects on TF and PPI activity in live human cells. Talus Bio and PRISM will share the costs of discovery research and development and any profits generated from out-licensing and commercialization of discovered drug products.

"We are delighted to partner with Talus on this exciting project," commented Dai Takehara, PRISM’s President and CEO. "We at PRISM have developed chemistries for PPI targets, but because of the complex nature of these targets, it is often challenging to properly model protein-protein interactions in a biochemical assay. Even when we are successful, we can interrogate only one target at a time, whereas Talus can profile hundreds to thousands of these targets in parallel and in their native environment. We believe that the combination of PRISM’s chemistry platform and Talus’s regulome profiling platform has the potential to discover a plethora of inhibitors against previously ‘undruggable’ TF and PPI targets and open a path for the development of novel therapeutics."

This collaboration is a pivotal step in establishing a systematic, scalable strategy to address TF and PPI targets. Together, the companies are creating a unified platform capable of revealing and modulating regulatory mechanisms that have remained undruggable for decades. The approach opens the door to long-needed therapies for transcriptionally driven diseases that lie beyond the capabilities of traditional small-molecule approaches.

Talus Bio will be attending the 2026 J.P. Morgan Healthcare Conference in San Francisco, January 12–15. For information on partnership and co-development opportunities, contact the Talus Bio team here. Follow Talus Bioscience on LinkedIn for the latest news and updates.

(Press release, Talus Bioscience, DEC 17, 2025, View Source [SID1234661516])

Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors

On December 17, 2025 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, reported the publication of a new study in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR) (Free AACR Whitepaper). The paper, titled "Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy," details results from Dr. Rodrigo Toledo and a leading team at the Vall d’Hebron Institute of Oncology (VHIO) in Barcelona, Spain. The study provides compelling clinical evidence that the company’s ultra-sensitive, tumor-informed molecular residual disease (MRD) assay, NeXT Personal, can effectively predict patient outcomes across a diverse set of cancers and immunotherapy modalities.

The study analyzed 202 patients with stage IV solid tumors—spanning 24 different cancer types—treated with immune checkpoint inhibitors and other immunotherapies. Utilizing a personalized testing approach that tracks up to ~1,800 tumor-specific variants unique to each patient’s tumor, the NeXT Personal test achieves ultrasensitive detection of small traces of circulating tumor DNA (ctDNA) from a patient’s blood sample.

Key findings published in Clinical Cancer Research include:

High Sensitivity: The test detected ctDNA in 98% of patients at baseline across all 24 tumor types, demonstrating robust performance even in a diverse set of cancers.
Early ctDNA Dynamics are Highly Prognostic: Patients who demonstrated decreases in ctDNA levels early in immunotherapy treatment had significantly higher overall survival. Conversely, patients with increasing ctDNA levels early while on immunotherapy had a zero percent overall response rate.
Durable ctDNA Clearance was a Positive Predictor: Patients who achieved durable molecular clearance (negative ctDNA for at least 180 days) had 100% overall survival (OS) in the study.
"We are excited about these results showing how NeXT Personal can be used to monitor therapy in late-stage metastatic patients," said Rich Chen, M.D., M.S., Chief Medical Officer and Executive Vice President, R&D at Personalis. "This study, together with our previous publications, shows the broad potential impact of ultrasensitive ctDNA testing, both in early and late stage cancers."

Dr. Rodrigo Toledo, Group Leader of the Biomarkers and Clonal Dynamics Laboratory at VHIO and senior author of the study, noted, "immunotherapy has revolutionized cancer care, but response patterns can be difficult to interpret using imaging alone. Our findings show that ultrasensitive ctDNA dynamics provide a clear, early molecular view of benefit or non-response, offering a powerful tool to guide patient management across a broad spectrum of solid tumors."

(Press release, Personalis, DEC 17, 2025, View Source [SID1234661515])